• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [22336 Records] Selected Records [0 Hits] [Clear]
Year Source Title
1998     TNO Pattern recognition: chances and possibilities for the care insurer
2009     NIHR Horizon Scanning Centre (NIHR HSC) Patupilone (EPO906) for recurrent epithelial ovarian cancer - refractory and/or resistant
2021     NIHR Health Services and Delivery Research programme Pay More Attention: a national mixed methods study to identify the barriers and facilitators to ensuring equal access to high quality hospital care and services for children and young people with learning disability and their families
2008     NIHR Health Technology Assessment programme Payment to healthcare professionals for patient recruitment to trials: systematic review and qualitative study
2012     Institute for Clinical Evaluative Sciences (ICES) Payments to Ontario physicians from ministry of health and long-term care sources, 1992/93 to 2009/10
2008     NIHR Horizon Scanning Centre (NIHR HSC) Pazopanib (GW786034) for advanced and/or metastatic renal cell carcinoma - first/second line
2011     NIHR Horizon Scanning Centre (NIHR HSC) Pazopanib (Votrient) for ovarian, fallopian or peritoneal cancer
2013     NIHR Horizon Scanning Centre (NIHR HSC) Pazopanib (Votrient) for renal cell carcinoma – adjuvant therapy
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pazopanib (Votrient) for the treatment of locally advanced and/or metastatic renal cell carcinoma
2013     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Pazopanib (Votrient®)
2011     National Institute for Health and Care Excellence (NICE) Pazopanib for the first line treatment of metastatic renal cell carcinoma
2010     NIHR Health Technology Assessment programme Pazopanib for the first line treatment of patients with advanced and/or metastatic renal cell carcinoma: a single technology appraisal
2014     HAYES, Inc. PCA3 detection test for prostate cancer
2009     HAYES, Inc. PCA3 detection test for prostate cancer
2013     Agency for Healthcare Research and Quality (AHRQ) PCA3 testing for the diagnosis and management of prostate cancer
2002     Norwegian Knowledge Centre for the Health Services (NOKC) PCI for acute myocardial infarction
2015     HAYES, Inc. PCSK9 inhibitors for cholesterol reduction: evolocumab
2024     Agency for Care Effectiveness (ACE) PCSK9 inhibitors for treating hypercholesterolaemia
1999     Health Council of the Netherlands Gezondheidsraad (GR) Peak exposures to organic solvents
2006     Agency for Healthcare Research and Quality (AHRQ) Pediatric anthrax: implications for bioterrorism preparedness
2007     HAYES, Inc. Pediatric bariatric surgery for morbid obesity
1999     Health Council of the Netherlands Gezondheidsraad (GR) Pediatric heart transplantation
2008     HAYES, Inc. Pediatric robotic-assisted surgery
2014     The Regional Health Technology Assessment Centre (HTA-centrum) Pediatric robotically assisted surgery for pyeoloplasty and fundoplication
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Pediatric stretchers and stretcher cribs: safety and guidelines
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Pediatric supraglottic airway devices: a review of clinical effectiveness
2004     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Pediatric tumours of the central nervous system
2014     NIHR Horizon Scanning Centre (NIHR HSC) Pediatric Vision Scanner for the detection of eye conditions in children
2007     Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS) Pedometer and accelerometer in assessing physical activity among children and adolescents
2017     Penn Medicine Center for Evidence-based Practice (CEP) Peer specialists in crisis response centers
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Peer support for diabetes, heart disease and HIV/AIDS: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Peer support programs for youth mental health
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Peer support programs for youth mental health
2019     NIHR Health Technology Assessment programme Peer-led walking programme to increase physical activity in inactive 60- to 70-year-olds: Walk with Me pilot RCT
2008     National Institute for Health and Care Excellence (NICE) Pegaptanib and ranibizumab for the treatment of age-related macular degeneration
2002     NIHR Horizon Scanning Centre (NIHR HSC) Pegaptanib for age-related macular degeneration - horizon scanning review
2005     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Pegaptanib for neovascular age-related macular degeneration
2010     NIHR Horizon Scanning Centre (NIHR HSC) Pegaptanib sodium (Macugen) for diabetic macular oedema
2015     NIHR Horizon Scanning Centre (NIHR HSC) Pegaspargase (Oncaspar) for acute lymphoblastic leukaemia
2022     National Institute for Health and Care Excellence (NICE) Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 778
2008     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Pegfilgrastim (Neulasta®) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy
2012     NIHR Horizon Scanning Centre (NIHR HSC) Peginesatide for anaemia in chronic kidney disease – first and second line
2011     NIHR Health Technology Assessment programme Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
2010     National Institute for Health and Care Excellence (NICE) Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
2006     Quality Improvement Scotland (NHS QIS ) Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
2006     National Institute for Health and Care Excellence (NICE) Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Peginterferon beta-1a (Plegridy®)
2020     National Institute for Health and Care Excellence (NICE) Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 624
2014     NIHR Horizon Scanning Centre (NIHR HSC) Peginterferon lambda-1a for hepatitis C
2016     NIHR Horizon Scanning Centre (NIHR HSC) Pegpleranib (Fovista) for neovascular age-related macular degeneration
2023     National Institute for Health and Care Excellence (NICE) Pegunigalsidase alfa for treating Fabry disease. NICE technology appraisal guidance 915
2016     NIHR Horizon Scanning Centre (NIHR HSC) Pegvaliase for the treatment of hyperphenylalaninaemia in adults with phenylketonuria – first line
2002     NIHR Horizon Scanning Centre (NIHR HSC) Pegvisomant for acromegaly - horizon scanning review
2001     NIHR Horizon Scanning Centre (NIHR HSC) Pegylated interferon alfa for hepatitis C - horizon scanning review
2004     NIHR Health Technology Assessment programme Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation
2007     Canadian Agency for Drugs and Technologies in Health (CADTH) Pegylated interferon combined with ribavirin for chronic hepatitis C virus infection: an economic evaluation
2015     NIHR Horizon Scanning Centre (NIHR HSC) Pelareorep (Reolysin) in combination with chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck – second line
2015     NIHR Horizon Scanning Centre (NIHR HSC) Pelareorep (Reolysin) with or without chemotherapy for metastatic malignant melanoma – second line
2016     NIHR Horizon Scanning Centre (NIHR HSC) Pelareorep in combination with paclitaxel for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer
2006     HAYES, Inc. Pelvic floor electrical stimulation for the treatment of urinary incontinence
2016     HAYES, Inc. Pelvic floor electrical stimulation for the treatment of urinary incontinence
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Pelvic floor repair systems: a review of the clinical-effectiveness, cost- effectiveness, and guidelines
2016     NIHR Horizon Scanning Centre (NIHR HSC) Pembrolizumab (Keytruda) - colorectal cancer: advanced or metastatic; high-level microsatellite instability – second line
2016     NIHR Horizon Scanning Centre (NIHR HSC) Pembrolizumab (Keytruda) - Hodgkin lymphoma: classical; relapsed or refractory – third and fourth line
2015     NIHR Horizon Scanning Centre (NIHR HSC) Pembrolizumab (Keytruda) for advanced or metastatic urothelial cancer – second line
2015     NIHR Horizon Scanning Centre (NIHR HSC) Pembrolizumab (Keytruda) for PD-L1 strong-positive metastatic non-small cell lung cancer – first line
2016     NIHR Horizon Scanning Centre (NIHR HSC) Pembrolizumab (Keytruda) for platinum-resistant, recurrent or metastatic head and neck cancer
2016     HAYES, Inc. Pembrolizumab (Keytruda) for unresectable or metastatic melanoma
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC)
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC)
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) for the treatment of advanced melanoma
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC)
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC)
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma. NICE technology appraisal guidance 766
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of renal cell carcinoma. NICE technology appraisal guidance 830
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma. NICE technology appraisal guidance 837
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer. NICE technology appraisal guidance 851
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 914
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for the adjuvant treatment of renal cell carcinoma
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Pembrolizumab for the treatment of advanced melanoma
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for treating high-risk early-stage triple-negative breast cancer
2021     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. NICE technology appraisal guidance 692
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for treating persistent, recurrent, or metastatic cervical cancer
2019     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 570
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies. NICE technology appraisal guidance 772
2018     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma. NICE technology appraisal guidance 540
2021     National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 709
2020     National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma. NICE technology appraisal guidance 661
2018     National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer. NICE technology appraisal guidance 531
2021     National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal). NICE technology appraisal guidance 674
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer. NICE technology appraisal guidance 801
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. NICE technology appraisal guidance 885
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. NICE technology appraisal guidance 939
2020     National Institute for Health and Care Excellence (NICE) Pembrolizumab with axitinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 650
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer. NICE technology appraisal guidance 770
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer. NICE technology appraisal guidance 904
2021     National Institute for Health and Care Excellence (NICE) Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer. NICE technology appraisal guidance 683
2021     National Institute for Health and Care Excellence (NICE) Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer. NICE technology appraisal guidance 737
2010     NIHR Horizon Scanning Centre (NIHR HSC) Pemetrexed disodium (Alimta) for recurrent or newly diagnosed metastatic head and neck cancer
2008     NIHR Horizon Scanning Centre (NIHR HSC) Pemetrexed disodium (Alimta) monotherapy as maintenance therapy for non-small cell lung cancer